Compare TAK & AJG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TAK | AJG |
|---|---|---|
| Founded | 1781 | 1927 |
| Country | Japan | United States |
| Employees | 47455 | 706000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.4B | 55.0B |
| IPO Year | N/A | 1995 |
| Metric | TAK | AJG |
|---|---|---|
| Price | $16.98 | $253.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $274.60 |
| AVG Volume (30 Days) | ★ 2.9M | 1.9M |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.24% | 1.32% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.16 |
| Revenue | N/A | ★ $6,159,600,000.00 |
| Revenue This Year | $0.16 | $30.53 |
| Revenue Next Year | $1.22 | $9.13 |
| P/E Ratio | ★ $41.25 | $78.99 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.99 | $190.75 |
| 52 Week High | $18.90 | $316.89 |
| Indicator | TAK | AJG |
|---|---|---|
| Relative Strength Index (RSI) | 67.74 | 76.30 |
| Support Level | $15.88 | $237.45 |
| Resistance Level | $18.86 | $262.02 |
| Average True Range (ATR) | 0.23 | 6.89 |
| MACD | 0.18 | 3.68 |
| Stochastic Oscillator | 90.76 | 92.65 |
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Founded in 1927 as a one-person agency, Gallagher's primary business is insurance brokerage, with a focus on serving middle-market companies. The company's risk management segment provides third-party claims adjustment to companies that choose to self-insure. Gallagher has about 72,000 employees and generates about a third of its revenue internationally, primarily in Australia, Canada, New Zealand, and the UK.